Eli Lilly beat earnings estimates, raised 2025 outlook, and saw increased investor buying.

Eli Lilly reported strong Q2 earnings with $6.31 EPS and $15.56 billion in revenue, surpassing estimates, and raised its 2025 EPS guidance to $21.75–23.00. Institutional investors increased holdings, including Phillips Financial Management and Cookson Peirce, while insiders bought over $2.8 million in shares. The stock, trading at $799.85, has a market cap of $757 billion and a consensus "Moderate Buy" rating with a $938.61 target.